Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4% - Here's What Happened

Key Points

• Hemab Therapeutics shares fell 8.4% to $47.30, with trading volume down 47% from its average. The stock has a $2.22 billion market capitalization and trades below profitability, with a P/E ratio of -1.92.
• The company reported a quarterly loss of $0.80 per share, missing analysts’ expected loss of $0.63. Analysts expect a full-year loss of approximately $3.09 per share.
• Analyst sentiment remains generally positive, with five Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $51.40.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report)'s stock price traded down 8.4% during trading on Thursday . The stock traded as low as $46.57 and last traded at $47.30. 166,261 shares changed hands during trading, a decline of 47% from the average daily volume of 312,116 shares. The stock had previously closed at $51.66.

Wall Street Analysts Forecast Growth

Several analysts recently commented on COAG shares. Wall Street Zen upgraded Hemab Therapeutics to a "hold" rating in a research report on Saturday, May 9th. Zacks Research raised shares of Hemab Therapeutics to a "hold" rating in a research note on Wednesday, May 27th. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a "buy" rating and a $36.00 price objective for the company. HC Wainwright raised their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings began coverage on Hemab Therapeutics in a report on Thursday, August 13th. They set a "sell (d+)" rating on the stock. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $51.40.

Hemab Therapeutics Stock Down 7.9%

The stock's fifty day moving average price is $40.76. The stock has a market cap of $2.22 billion and a P/E ratio of -1.92.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). As a group, equities analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the business's stock in a transaction on Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source